N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 10277-10281

  Zanaletti, Riccardo ^a   Bettinetti, Laura ^a   Castaldo, Cristiana ^a   Ceccarelli, Ilaria ^a   Cocconcelli, Giuseppe ^a   Comery, Thomas A ^b   Dunlop, John ^b   Genesio, Eva ^a   Ghiron, Chiara ^a   Haydar, Simon N ^b   Jow, Flora ^b   Maccari, Laura ^a   Micco, Iolanda ^a   Nencini, Arianna ^a   Pratelli, Carmela ^a   Scali, Carla ^a   Turlizzi, Elisa ^a   Valacchi, Michela ^a  

^a Siena Biotech SpA   (Italy)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUNGAROTOXIN RECEPTOR; DIZOCILPINE; N [5 (5 FLUOROPYRIDIN 3 YL) 1H PYRAZOL 3 YL] 4 PIPERIDIN 1 YLBUTYRAMIDE; NICOTINIC AGENT; SEN 15924; SEN 78702; UNCLASSIFIED DRUG; WAY 361789; WYE 308775;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SCHIZOPHRENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BRAIN; CALCIUM; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; COGNITION; CRICETINAE; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, MOLECULAR; NICOTINIC AGONISTS; PIPERIDINES; PYRAZOLES; RATS; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870015755     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3013568     Document Type: Article

References (17)

1. Dani, J. A.; Bertrand, D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system Annu. Rev. Pharmacol. Toxicol. 2007, 47, 699-729
2. D'hoedt, D.; Bertrand, D. Nicotinic acetylcholine receptors: an overview on drug discovery Expert Opin. Ther. Targets 2009, 4, 395-411
3. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 2009, 78, 703-711
4. Seguela, P.; Wadiche, J.; Dineley, M. K.; Dani, J. A.; Patrick, J. W. Molecular cloning, functional properties, and distribution of rat brain alpha7: a nicotinic cation channel highly permeable to calcium J. Neurosci. 1993, 13, 596-604
5. Freedman, R.; Coon, H.; Myles-Worsley, M.; Orr-Urtreger, A.; Olincy, A.; Davis, A.; Polymeropoulous, M.; Holik, J.; Hopkins, J.; Hoff, M.; Rosenthal, J.; Waldo, M. C.; Reimherr, F.; Wender, P.; Yaw, J.; Young, D. A.; Breese, C. R.; Adams, C.; Patterson, D.; Adler, L. E; Kruglyak, L.; Leonard, S.; Byerley, W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 587-592
6. Guan, Z.-Z.; Zhang, X.; Ravid, R.; Nordberg, A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease J. Neurochem. 2000, 74, 237-243
7. Lippiello, P. M.; Bencherif, M.; Hauser, T. A.; Jordan, K. G.; Letchworth, S. R.; Mazurov, A. A. Nicotinic receptors as targets for therapeutic discovery Expert Opin. Drug Discovery 2007, 2, 1185-1203
8. Freedman, R.; Adams, C. E.; Leonard, S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia J. Chem. Neuroanat. 2000, 20, 299-306
9. Kem, W. R. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21) Behav. Brain Res. 2000, 113, 169-181
10. Mazurov, A. A.; Speake, J. D.; Yohannes, D. Discovery and development of α7 nicotinic acetylcholine receptor modulators J. Med. Chem. 2011, 54, 7943-7961
11. Zanaletti, R.; Bettinetti, L.; Castaldo, C.; Cocconcelli, G.; Comery, T.; Dunlop, J.; Gaviraghi, G.; Ghiron, C.; Haydar, S. N.; Jow, F.; Maccari, L.; Micco, I.; Nencini, A.; Scali, C.; Turlizzi, E.; Valacchi, M. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl-[1,4]diazepan-1-yl)-pentanoic acid [5-(4-methoxy-phenyl)-1 H -pyrazol-3-yl]-amide (SEN15924, WAY-361789) J. Med. Chem. 2012, 10, 4806-4823
12. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 26, 7559-7583
13. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: highlights and hang-ups J. Med. Chem. 2006, 17, 5029-5046
14. Feuerbach, D.; Nozulak, J.; Lingenhoehl, K.; McAllister, K.; Hoyer, D. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor α7 selective agonist Neurosci. Lett. 2007, 416, 61-65
15. Papke, R. L.; Porter Papke, J. K. Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis Br. J. Pharmacol. 2002, 137, 49-61
16. Wishka, D. G.; Walker, D. P.; Yates, K. M.; Reitz, S. C.; Jia, S.; Myers, J. K.; Olson, K. L.; Jacobsen, E. J.; Wolfe, M. L.; Groppi, V. E.; Hanchar, A. J.; Thornburgh, B. A.; Cortes-Burgos, L. A.; Wong, E. H.; Staton, B. A.; Raub, T. J.; Higdon, N. R.; Wall, T. M.; Hurst, R. S.; Walters, R. R.; Hoffman, W. E.; Hajos, M.; Franklin, S.; Carey, G.; Gold, L. H.; Cook, K. K.; Sands, S. B.; Zhao, S. X.; Soglia, J. R.; Kalgutkar, A. S.; Arneric, S. P.; Rogers, B. N. Discovery of N -[(3 R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3- c ]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship J. Med. Chem. 2006, 49, 4425-4436
17. Prickaerts, J.; Van Goethem, N. P.; Chesworth, R.; Shapiro, G.; Boess, F. G.; Methfessel, C.; Reneerkens, O. A. H.; Flood, D. G.; Hilt, D.; Gawryl, M.; Bertrand, S.; Bertrand, D.; König, G. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist,improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors Neuropharmacology 2011, 2, 1099-1110